Healthy 17 year-old Utah high school athlete develops 3 blood clots in his brain immediately after Covid Vaccine

Healthy 17 year-old Utah high school athlete develops 3 blood clots in his brain immediately after Covid Vaccine

ABC News gets marks for reporting this story when so many similar stories are covered up. For example we are still wating for proof of life of that nurse back at the start of the injections, that passed out right after getting the shot on camera, even though given the massive number of deaths and serious effects of this technology, what happened to that one person only matters in terms of the extent to which vaccine companies are controlling what we can know. But ABC looses marks for not telling us which vaccine clearly caused this mess. The only practical response is don’t get any of them till we know what they do.

MEANWHILE:

Pfizer, AstraZeneca COVID vaccines probed in Europe after reports of heart inflammation, rare nerve disorder

Europe’s drug regulator says it’s evaluating an assortment of potential side effects following inoculation with leading COVID-19 vaccines, including heart inflammation, facial swelling and a rare nerve-degenerating disorder. Yet in most circumstances, it’s not clear whether the vaccines are to blame. 

In AstraZeneca’s case, the European Medicines Agency’s safety committee, known as PRAC for short, said it’s examining reports of Guillain-Barre syndrome (GBS) among people who received the drugmaker’s COVID-19 vaccine, according to a report released on Friday. The agency is tracking the data for all coronavirus shots as part of its routine safety procedures.

GBS syndrome is a rare disorder that causes nerve inflammation and can result in pain, numbness, muscle weakness and difficulty walking. GBS was previously identified by regulators as a potential adverse side effect that required monitoring following AstraZeneca’s jab, the EMA said. The regulator asked AstraZeneca to provide more detailed data and an analysis of all reported GBS cases for its next safety report, which are required on a monthly basis.

Concerns of rare but serious blood clots among AstraZeneca vaccine recipients have beset Europe’s vaccine rollout for months. In early April, the EMA said the unusual blood clots with low blood platelets should be listed as very rare side effect for the company’s vaccine, marketed as Vaxzevria.